Antibiotic
resistance is a growing global health threat, demanding
urgent responses. Tetracyclines, a widely used antibiotic class, are
increasingly succumbing to antibiotic resistance; generating novel
analogues is therefore a top priority for public health. Fungal tetracyclines
provide structural and enzymatic diversity for novel tetracycline
analogue production in tractable heterologous hosts, like yeasts,
to combat antibiotic-resistant pathogens. Here, we successfully engineered Saccharomyces cerevisiae (baker’s yeast) and Saccharomyces boulardii (probiotic yeast) to produce
the nonantibiotic fungal anhydrotetracycline, TAN-1612, in synthetic
defined medianecessary for clean purificationsthrough
heterologously expressing TAN-1612 genes mined from the fungus, Aspergillus niger ATCC 1015. This was accomplished
via (i) a promoter library-based combinatorial pathway optimization
of the biosynthetic TAN-1612 genes coexpressed with a putative TAN-1612
efflux pump, reducing TAN-1612 toxicity in yeasts while simultaneously
increasing supernatant titers and (ii) the development of a medium-throughput
UV–visible spectrophotometric assay that facilitates TAN-1612
combinatorial library screening. Through this multipronged approach,
we optimized TAN-1612 production, yielding an over 450-fold increase
compared to previously reported S. cerevisiae yields. TAN-1612 is an important tetracycline analogue precursor,
and we thus present the first step toward generating novel tetracycline
analogue therapeutics to combat current and emerging antibiotic resistance.
We also report the first heterologous production of a fungal polyketide,
like TAN-1612, in the probiotic S. boulardii. This highlights that engineered S. boulardii can biosynthesize complex natural products like tetracyclines, setting
the stage to equip probiotic yeasts with synthetic therapeutic functionalities
to generate living therapeutics or biocontrol agents for clinical
and agricultural applications.